Explanipedia

Assessing buprenorphine treatment utilization and SAMHSA DATA waiver provider distribution in 2021: a real-world analysis in California Open

Yun Wang, Tao Hu, Chih-Hung Chang, Matthew Heshmatipour, Jeff J. Guo , et al. · 2025

Professional Coaching to Reduce Physician Burnout: A Randomized Clinical Trial Open

Joshua Khalili, Karen Miotto, Tisha Wang, John N. Mafi, Elizabeth Kyababchyan , et al. · 2025

Background Physician burnout is a public health crisis. While one-on-one professional coaching reduces physician burnout, its costs may limit widespread use. Small group professional coaching could offer a more scalable solution, but its e…

A Neuroimmune Modulator for Alcohol Use Disorder Open

Lara A. Ray, Lindsay R. Meredith, Erica N. Grodin, Malia A. Belnap, Steven J. Nieto , et al. · 2025

Importance The neuroimmune system represents a promising target for novel medications for alcohol use disorder (AUD). Ibudilast is a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE) 3, PDE4, PDE10, and PDE11, and m…

Effects of a novel <span>GABA</span>‐B positive allosteric modulator, <span>ASP8062</span>, on alcohol cue‐elicited craving and naturalistic alcohol consumption in a multisite randomized, double‐blind, placebo‐controlled trial Open

Joseph P. Schacht, Lara A. Ray, Robert Miranda, Daniel E. Falk, Megan L. Ryan , et al. · 2024

Background The γ‐aminobutyric acid‐B (GABA B ) receptor is a promising target for the development of new medications to treat alcohol use disorder (AUD). The GABA B agonist baclofen has been reported to reduce alcohol consumption but is as…

Change of opioid prescribing before and after the COVID pandemic in California, 2017-2022 Open

Yun Wang, Hao Wang, Duncan Watson, Kabir Snell Jose, Ryan Stofer , et al. · 2024

Background The coronavirus disease pandemic 2019 (COVID-19) has profoundly affected healthcare access, but its impact on high-risk opioid prescribing patterns remains unclear. The study aimed to investigate the changes in high-risk opioid …

Does sex moderate the effects of early life stress on peripheral inflammation in alcohol use disorder? A preliminary investigation Open

Dylan Kirsch, Erica N. Grodin, Artha Gillis, Karen Miotto, Lara A. Ray · 2024

Measurement Bias in Machine Learning-Enhanced Opioid Risk Scoring Systems Open

Yun Wang, Drake Waston, Hao Wang, Karen Miotto, Kabir Snell Jose , et al. · 2024

Over the past two decades, Prescription Drug Monitoring Programs (PDMPs), augmented by machine learning-empowered clinical decision support (CDS) tools, have become essential in monitoring opioid prescriptions. The CDS tool employs proprie…

Assessing Buprenorphine Treatment Utilization and SAMHSA DATA Waiver Provider Distribution in 2021: A Real-World Analysis in California Open

Yun Wang, Tao Hu, Moom R. Roosan, Chih-Hung Chang, Matthew Heshmatipour , et al. · 2024

Qualified clinicians must obtain a practitioner waiver (i.e., “DATA-waiver”) to offer buprenorphine, a medication for opioid use disorder (OUD). However, many counties experience fewer buprenorphine prescriptions due to factors such as “DA…

A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial Open

Lara A. Ray, Wave‐Ananda Baskerville, Steven J. Nieto, Erica N. Grodin, Craig K. Enders , et al. · 2023

Before and During the First COVID-19 Surge: Work Conditions, Burnout, and Mental Health Among Resident Physicians in a Department of Psychiatry in the USA Open

Alpna Agrawal, K De La Torre, Conisha Cooper, Jeremy Flores, Karen Miotto , et al. · 2023

Alcohol Use Among Treatment-Seeking Individuals with Opioid Use Disorder Open

Wave‐Ananda Baskerville, Erica N. Grodin, Johnny Wei‐Bing Lin, Karen Miotto, Larissa J. Mooney , et al. · 2023

These findings suggest that alcohol or binge alcohol use is associated with significantly lower odds of opioid use on a given day, which was not related to gender or age. The prevalence of opioid use remained high on both alcohol use and n…

Baseline C-reactive protein levels are predictive of treatment response to a neuroimmune modulator in individuals with an alcohol use disorder: a preliminary study Open

Erica N. Grodin, Lindsay R. Meredith, Elizabeth M. Burnette, Karen Miotto, Michael R. Irwin , et al. · 2022

Background: Inflammation is implicated in alcohol use disorder (AUD). Ibudilast, a neuroimmune modulator, shows promise for the treatment of AUD. Elevated inflammation, indicated by high levels of C-reactive protein (CRP), represent…

Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial Open

Erica N. Grodin, Steven J. Nieto, Lindsay R. Meredith, Elizabeth M. Burnette, Joseph O’Neill , et al. · 2022

Ibudilast, a neuroimmune modulator, shows promise as a pharmacotherapy for alcohol use disorder (AUD). In vivo administration of ibudilast reduces the expression of pro‐inflammatory cytokines in animal models, but its effects on markers of…

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder Open

Elizabeth M. Burnette, Steven J. Nieto, Erica N. Grodin, Lindsay R. Meredith, Brian Hurley , et al. · 2022

Alcohol use disorder (AUD) is a highly prevalent but severely under-treated disorder, with only three widely-approved pharmacotherapies. Given that AUD is a very heterogeneous disorder, it is unlikely that one single medication will be eff…

Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers Open

Erica N. Grodin, Elizabeth M. Burnette, ReJoyce Green, Aaron C. Lim, Karen Miotto , et al. · 2021

Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial Open

Erica N. Grodin, Spencer Bujarski, Brandon Towns, Elizabeth M. Burnette, Steven J. Nieto , et al. · 2021

Ibudilast, a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE)-3, -4, -10, and -11, and macrophage migration inhibitory factor (MIF), shows promise as a novel pharmacotherapy for alcohol use disorder (AUD). However,…

Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial Open

Lara A. Ray, ReJoyce Green, Craig K. Enders, Adam M. Leventhal, Erica N. Grodin , et al. · 2021

These findings suggest that smoking cessation and drinking reduction can be concomitantly targeted with pharmacotherapy and that while varenicline alone may be sufficient as a smoking cessation aid in heavy-drinking smokers, the combinatio…

Ibudilast moderates the effect of mood on alcohol craving during stress exposure. Open

Lindsay R. Meredith, ReJoyce Green, Erica N. Grodin, Marie Chorpita, Karen Miotto , et al. · 2021

Neuroinflammation is implicated in the development and maintenance of alcohol use disorder (AUD) and neuroimmune therapeutics show promise in treating AUD. Proinflammatory signaling contributes to progressive elevations in the dysfunction …

Psychological Distress Among Women Healthcare Workers: A Health System's Experience Developing Emotional Support Services During the COVID-19 Pandemic Open

Jesse Sanford, Alpna Agrawal, Karen Miotto · 2021

Ensuring the mental health and well-being of the healthcare workforce globally, especially women healthcare workers (HCWs), is an ongoing challenge that has been accentuated by the novel coronavirus (COVID-19) pandemic. Already at high ris…

Understanding the Experiences of First-Generation Medical Students: Implications for a Diverse Physician Workforce Open

Ruby Romero, Karen Miotto, Alejandra Casillas, Jesse Sanford · 2020

Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent Open

Aaron C. Lim, Dara G. Ghahremani, Erica N. Grodin, ReJoyce Green, Spencer Bujarski , et al. · 2019

2017 Annual Report of the ABPN Open

Board Chair, Kerry H. Levin, Robert J. Ronis, George A. Keepers, Joshua Goodman , et al. · 2018

The following is an edited/abbreviated version of the 2017 Report of the American Board of Psychiatry and Neurology, Inc. The full report can be obtained from the American Board of Psychiatry and Neurology ( www.abpn.com ).

Differences in the subjective and motivational properties of alcohol across alcohol use severity: application of a novel translational human laboratory paradigm Open

Spencer Bujarski, David Jentsch, Daniel Roche, Vijay A. Ramchandani, Karen Miotto , et al. · 2018

Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial Open

Lara A. Ray, ReJoyce Green, Daniel Roche, Spencer Bujarski, Emily E. Hartwell , et al. · 2017

Background Genetic variation in the endogenous opioid system has been identified as 1 potential source of individual variability in naltrexone treatment outcomes. The majority of naltrexone pharmacogenetic studies have focused on a particu…

High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System Open

Yih‐Ing Hser, Larissa J. Mooney, Andrew J. Saxon, Karen Miotto, Douglas S. Bell , et al. · 2017

Objectives: Elevated mortality has been observed among individuals with opioid use disorder (OUD) treated in addiction specialty clinics or programs. Information about OUD patients in general healthcare settings is needed in light of the c…

Chronic pain among patients with opioid use disorder: Results from electronic health records data Open

Yih‐Ing Hser, Larissa J. Mooney, Andrew J. Saxon, Karen Miotto, Douglas S. Bell , et al. · 2017

Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial Open

Lara A. Ray, Spencer Bujarski, Steven Shoptaw, Daniel Roche, Keith G. Heinzerling , et al. · 2017

Adaptation and Evaluation of Military Resilience Skills Training for Pediatric Residents Open

Brenda Bursch, Jessica C. Lloyd, Catherine Mogil, Kanchana Wijesekera, Karen Miotto , et al. · 2017

Background: An evidence-based trauma-informed resilience skills training program developed for deployed military personnel was adapted and pilot-tested with pediatric residents. We anticipated high satisfaction ratings and changes in knowl…

A Call to Action Open

Matthew Goldenberg, Sameer Hassamal, Waguih William IsHak, Margaret Haglund, Karen Miotto , et al. · 2016

Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.To the Editor: While the epidemic of opioid overdoses is reaching the national consciousness, we fear an…

A Pilot Study of the Safety and Initial Efficacy of Ivermectin for the Treatment of Alcohol Use Disorder Open

Daniel Roche, Megan M. Yardley, Katy Lunny, Stan G. Louie, Daryl L. Davies , et al. · 2016

Background Ivermectin ( IVM ) is an antiparasitic agent that has been shown to reduce alcohol intake in mice, suggesting IVM as a potential treatment for alcohol use disorder ( AUD ). However, the safety profile of IVM administered in comb…

Karen Miotto YOU? Author Swipe